PPPolina A. Pyzhyanova

Polina A. Pyzhyanova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Polina A. Pyzhyanova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New Prospects for the Application of Om-85: A Literature Review

    by Leyla S. Namazova-Baranova, Polina A. Domasheva, Kamilla E. Efendieva, Л. С. Намазова-Баранова, П. А. Домашева, К. Е. Эфендиева

    The bacterial lysate OM-85 is a well-studied immunomodulator with a favorable safety profile. Its efficacy in the prevention and combination therapy of recurrent respiratory infections in children has been confirmed by numerous clinical trials, which have demonstrated a reduction in infection frequency, antibiotic use, and disease duration. Mechanistically, OM-85 induces interferon synthesis, enhances secretory IgA production, and modulates the T-helper (Th) balance by promoting a Th1-skewed response and activating regulatory T cells. These immunomodulatory properties open up prospects for its use as part of combination therapy in T2-mediated conditions, including bronchial asthma, allergic rhinitis, and atopic dermatitis. Promising directions for further research include evaluating the efficacy of extended OM-85 courses lasting up to 6–9 months, as well as investigating its role in the primary prevention of allergic diseases. Thus, the potential of OM-85 is not limited to the prevention of respiratory infections and may extend to the development of novel approaches for managing a broad range of immune-mediated disorders.

  • Open Access

    Possibility of switching of a biological drug when treating childhood asthma (A clinical case)

    by P. A. Pyzhyanova, S. V. Zaytseva, A. U. Tomilova, A. A. Ibragimova

    Introduction. Genetically engineered biological drugs (GEBD) are widely used in the treatment of children with uncontrolled bronchial asthma (BA). In Russia, several GEBD have been registered for the treatment of children and adolescents with asthma, including anti-immunoglobulin E/anti-IgE (omalizumab), anti-interleukin 5/anti-IL-5Ra (mepolizumab), and anti-IL-4Ra (dupilumab). The choice of GEBD depends on the BA phenotype and genotype. However, in pediatric practice, the difficulty of determining a BA endotype complicates the search for an effective drug. For this reason, there is a possibility of insufficient effectiveness of the recommended expensive therapy and the need to revise the treatment of GEBD in accordance with the phenotypic features of the disease.Clinical case description. The paper presents a dynamic follow-up of a 7-year-old child with severe asthma and concomitant atopic dermatitis (AD) receiving GEBD therapy. The initial biological drug was omalizumab. Subsequently, due to insufficient control of the symptoms of the disease and exacerbation of severe atopic dermatitis, a switch to dupilumab was performed. The change in GEBD contributed to achieving control over BA symptoms and a relief of the skin condition.Conclusions. Our observation shows the effectiveness and safety of switching between omalizumab to dupilumab in children with severe asthma and concomitant AD. Further research is needed to clarify the clinical profile of patients in order to determine predictors of an effective choice of biotherapy and resolve the issue of switching to various monoclonal antibodies.

  • Open Access

    New Opportunities of Dupilumab in Achieving Disease Control in Preschool Age Patients with Atopic Dermatitis: Clinical Case

    by Julia G. Levina, Polina A. Pyzhyanova, Vera G. Kalugina, Kamilla E. Efendieva, Elena A. Vishneva, Anna A. Alekseeva, Leyla S. Namazova-Baranova

    Background. Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases in children. It manifests during the first year of life in majority of cases. Early AD manifestation is a risk factor for the development of other atopic spectrum diseases in the future. Nowadays, the ability of the dupilumab, as a genetically engineered biologic drug (GEBD), to modify the disease course, to reduce the frequency of AD persistence and the possibility of multimorbid atopic phenotype development is widely discussed. Thus, dupilumab management in young children with early onset and severe course arouses specific interest. Clinical case description. This article demonstrates the experience of effective administration of GEBD dupilumab in 4-year old patient with severe AD and comorbid food allergies. Continuous therapy for 12 weeks allowed to recover disease’s skin manifestations. No adverse events were reported. Conclusion. Long-term continuous dupilumab administration in children aged from 6 months to 5 years has proven its efficacy and acceptable safety profile. The potential disease-modifying effect of dupilumab is especially significant for young and preschool children due to the high risk atopic multimorbidity developing during this period.


  • Open Access

    Successful Dupilumab Administration in Adolescent with Alopecia Areata and Atopic Dermatitis: Clinical Case

    by Eduard T. Ambarchyan, Vladislav V. Ivanchikov, Anastasiya D. Kuzminova, Polina A. Pyzhyanova, Liana R. Agliullova

    Background. Alopecia areata is an autoimmune disease characterized by hair loss that develops with the involvement of CD8+ T-cells of the immune system and cytokines produced by T-helper 2 cells (Th2). Efficacy of alopecia areata management is limited. The one potentially effective variant for treatment of severe forms of alopecia areata complicated with atopic dermatitis (AD) is genetically engineered biologic drug dupilumab (interleukin 4 receptor antagonist that suppresses Th2 response). Clinical case description. 11 years old boy was admitted to the dermatology department with complaints on aggravation of AD and numerous hair loss foci. Dupilumab, 300 mg, was prescribed once every 4 weeks. Severity of erythematous papular rashes significantly decreased within 9 months, as well as irritation intensity. Complete restoration of hair growth was noted in areas of former alopecia areata foci. Conclusion. Dupilumab can be effective in the management of severe forms of alopecia areata in children with comorbid AD. Clinical studies on the efficacy and safety of such therapy are needed to confirm this hypothesis.

  • Open Access

    Commitment of health workers and various population groups to vaccination

    by Diana V. Sutovskaya, Polina A. Pyzhyanova, Екатерина Владимировна Габдуллина, Anastasia A. Makunts, Анна Витальевна Кузьменко, Анастасия Ашотовна Макунц

    Introduction. The relatively stable incidence of most controlled infections shifts the focus of public attention from the need for vaccination to the likelihood of post-vaccination complications. Aim. To examine the adherence of various population groups and health workers to vaccine prophylaxis and analyze the reasons for anti-vaccination scepticism. Materials and methods. A survey was conducted on the attitudes towards vaccination among one thousand nine hundred thirty nine respondents including 485 doctors of various specialties (163 pediatricians, 86 surgeons, 85 obstetricians-gynecologists, 76 neurologists, 75 neonatologists), 117 nurses, 295 parents, 1042 students. The significance of differences was assessed using Student’s t-test. Results. An insufficient level of adherence to vaccine prophylaxis has been established: 43.1% of parents vaccinate their children selectively, 35.4% according to the national calendar, 17.1% refuse categorically, and 4.4% have a medical refusal. The main reason for refusal is fear of complications (30%). Less than half receive information from health workers (45.6%), the main source being the media (49.1%). Among health workers, adherence to vaccine prophylaxis is highest among pediatricians (86.1%), significantly lower among neurologists (35.6%), surgeons (43.7%), obstetricians-gynecologists (62.6%), nurses (79.5%). The main reason for distrust of vaccination is fear of post-vaccination complications, narrow specialists more often choose the answer “better to get sick”. Among medical university students there is a significantly higher adherence among senior students in paediatrics (63.6%) compared to students in undergraduate (40.8%) and medical school (48.8%). However, 5% of those surveyed do not plan to vaccinate their children in the future. Polytechnic students have a more negative attitude towards vaccination accounted for only 36.4% vaccinated according to the National Calendar and 30% do not plan to vaccinate their children in the future. Conclusion. There is a clear need for additional training programs on vaccination to raise the awareness of health care workers on this issue, which will provide a strong rationale for the importance of immunization to patients and their parents.


  • Open Access

    The impact of the coronavirus pandemic on the condition of newborns depending on the mother’s COVID status: a retrospective study

    by Diana V. Sutovskaya, Alla V. Burlutskaya, Elena M. Garbuzova, Anastasia A. Makunts, Anna V. Kuzmenko, Ekaterina V. Gabdullina, Polina A. Pyzhyanova, Lubov V. Gorbacheva

    Background. A novel coronavirus infection in newborns seems to be an unexplored problem, which encourages pediatric specialists to conduct in-depth research in this direction. The aim  of the study is the impact of COVID status of mothers on the condition of newborns. Material and  methods. A retrospective analysis of 554 newborn histories (form 097/y) born from January 2021 to May 2022 was carried out in the Maternity Hospital in Krasnodar: 226 children from SARS-CoV-2 positive women at the time of delivery (group 1), 165 children from women who had SARS-CoV-2 during pregnancy (group 2) and 165 children from women who did not have SARS-CoV-2 in history during pregnancy (control group). Results. 42% of newborns from group 1 had positive results of the PCR (polymerase chain reaction) study, of which 36% had pneumonia. The frequency of preterm birth was: 29% in the group 1, 21% in the group 2, 13% in the control group. The gestational age 32–34 weeks was more common in group 1. Children from the group 1 had a more severe condition when assessed on the APGAR scale both at the first and fifth minutes. Congenital pneumonia was more common among patients of the groups 1 and 2 relative to the control, children from the group 1 more often needed respiratory support compared with the group 2 and control group. Conclusions: The SARS-CoV-2 virus was verified in 42% of children born to mothers with a positive PCR at the time of birth, while every third disease was accompanied by the development of pneumonia. Coronavirus infection, regardless of the mother’s COVID status, is a risk factor for preterm birth, congenital pneumonia, and asphyxia. COVID-positive maternal and neonatal status is associated with an increased need for respiratory support.